Journal of Cancer Research and Therapeutics

LETTER TO THE EDITOR
Year
: 2017  |  Volume : 13  |  Issue : 2  |  Page : 384--386

Adult rhabdomyosarcoma: Multimodality management and results


Abhijeet Ashok Salunke, Jaymin Shah, Nayan Gupta, Jyotindra Pandit 
 Department of Orthopedic Onco Surgery, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India

Correspondence Address:
Abhijeet Ashok Salunke
Department of Orthopedic Onco Surgery, Room No.13, Gujarat Cancer Research Institute, Ahmedabad
India




How to cite this article:
Salunke AA, Shah J, Gupta N, Pandit J. Adult rhabdomyosarcoma: Multimodality management and results.J Can Res Ther 2017;13:384-386


How to cite this URL:
Salunke AA, Shah J, Gupta N, Pandit J. Adult rhabdomyosarcoma: Multimodality management and results. J Can Res Ther [serial online] 2017 [cited 2022 Nov 27 ];13:384-386
Available from: https://www.cancerjournal.net/text.asp?2017/13/2/384/180606


Full Text

Sir,

We read with interest the article by Khosla et al. who have demonstrated that RMS in adults has poor prognosis as compared with childhood RMS. Adult RMS should, therefore, be treated aggressively with multidisciplinary approach comprising surgery, radiation, and chemotherapy to achieve cure and prolonged survival.[1]

Was there any difference in survival rate in the group treated with surgery and radiotherapy and group treated with surgery, radiotherapy, and chemotherapy? According to Little et al., treatment consisted of radiation alone in 11%, radiation and surgery in 18%, radiation and chemotherapy in 34%, and all the three modalities in 37%.[2] It would be of great interest to know what percentage of cases received multimodality treatment in the current series.

There is a high incidence of regional lymph node metastases in adult rhabdomyosarcoma ranging from 33% to 46%.[2],[3] Similarly, it would be of great interest to know how many cases in the current study had lymph node metastasis and what was the management.

The overall survival (OVS) and disease-free survival (DFS) are variable according to the site of tumor; so was there any difference in OVS and DFS in the current series in extremity RMS and nonextremity RMS?

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Khosla D, Sapkota S, Kapoor R, Kumar R, Sharma SC. Adult rhabdomyosarcoma: Clinical presentation, treatment, and outcome. J Cancer Res Ther 2015;11:830-4.
2Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, et al. Adult rhabdomyosarcoma: Outcome following multimodality treatment. Cancer 2002;95:377-88.
3Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg 2001;234:215-23.